JP2021532094A5 - - Google Patents

Info

Publication number
JP2021532094A5
JP2021532094A5 JP2021502836A JP2021502836A JP2021532094A5 JP 2021532094 A5 JP2021532094 A5 JP 2021532094A5 JP 2021502836 A JP2021502836 A JP 2021502836A JP 2021502836 A JP2021502836 A JP 2021502836A JP 2021532094 A5 JP2021532094 A5 JP 2021532094A5
Authority
JP
Japan
Prior art keywords
stem cells
human
pharmaceutical composition
mitochondrial
cells
Prior art date
Application number
JP2021502836A
Other languages
English (en)
Japanese (ja)
Other versions
JP7458368B2 (ja
JPWO2020021539A5 (https=
JP2021532094A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2019/050826 external-priority patent/WO2020021539A1/en
Publication of JP2021532094A publication Critical patent/JP2021532094A/ja
Publication of JPWO2020021539A5 publication Critical patent/JPWO2020021539A5/ja
Publication of JP2021532094A5 publication Critical patent/JP2021532094A5/ja
Application granted granted Critical
Publication of JP7458368B2 publication Critical patent/JP7458368B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021502836A 2018-07-22 2019-07-22 筋疾患のミトコンドリア増強療法 Active JP7458368B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862701783P 2018-07-22 2018-07-22
US62/701,783 2018-07-22
US201862753937P 2018-11-01 2018-11-01
US62/753,937 2018-11-01
PCT/IL2019/050826 WO2020021539A1 (en) 2018-07-22 2019-07-22 Mitochondrial augmentation therapy of muscle diseases

Publications (4)

Publication Number Publication Date
JP2021532094A JP2021532094A (ja) 2021-11-25
JPWO2020021539A5 JPWO2020021539A5 (https=) 2022-06-28
JP2021532094A5 true JP2021532094A5 (https=) 2022-06-28
JP7458368B2 JP7458368B2 (ja) 2024-03-29

Family

ID=69181527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021502836A Active JP7458368B2 (ja) 2018-07-22 2019-07-22 筋疾患のミトコンドリア増強療法

Country Status (4)

Country Link
US (1) US11951135B2 (https=)
EP (1) EP3823640A4 (https=)
JP (1) JP7458368B2 (https=)
WO (1) WO2020021539A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2741757B1 (en) 2011-09-11 2018-05-16 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
US12551504B2 (en) 2018-07-22 2026-02-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of pancreatic diseases
US12329781B2 (en) 2018-07-22 2025-06-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of renal diseases
JP2021531288A (ja) 2018-07-22 2021-11-18 ミノヴィア セラピューティクス リミテッド 眼疾患のミトコンドリア増強療法
WO2020021536A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
JP7524157B2 (ja) 2018-07-22 2024-07-29 ミノヴィア セラピューティクス リミテッド 脳疾患のミトコンドリア増強療法
JP7458368B2 (ja) 2018-07-22 2024-03-29 ミノヴィア セラピューティクス リミテッド 筋疾患のミトコンドリア増強療法
CA3172402A1 (en) 2020-03-31 2021-10-07 Minovia Therapeutics Ltd. Mitochondria-enriched genetically engineered cells and uses thereof
WO2021199032A1 (en) * 2020-03-31 2021-10-07 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy
US20240382534A1 (en) * 2021-12-13 2024-11-21 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for myelodysplastic syndrome
CN117883479A (zh) * 2023-11-02 2024-04-16 上海市第六人民医院 人源线粒体在制备治疗跟腱损伤的药物中的应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1150433A (zh) 1994-03-30 1997-05-21 米托科公司 线粒体缺陷相关疾病的诊断,治疗以及细胞和动物模型
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
JP2002538167A (ja) 1999-03-03 2002-11-12 バイオジェン インコーポレイテッド 脂質の代謝および貯蔵を調節する方法
GB2350565A (en) 1999-05-28 2000-12-06 Johnson & Johnson Medical Ltd Biological wound dressings comprising mitochondria
DE19937348A1 (de) 1999-08-11 2001-02-22 Aventis Cropscience Gmbh Nukleinsäuremoleküle aus Pflanzen codierend Enzyme, die an der Stärkesynthese beteiligt sind
US7238727B2 (en) 2000-10-13 2007-07-03 Chugai Seiyaku Kabushiki Kaisha Compositions for improving lipid metabolism
US20030040475A1 (en) 2001-01-16 2003-02-27 Yasuhiro Toba Agents for improving lipid metabolism and reducing high blood pressure
US7339090B2 (en) 2001-02-13 2008-03-04 Avigenics, Inc. Microinjection devices and methods of use
JP4603192B2 (ja) 2001-05-10 2010-12-22 株式会社カネカ 毛髪頭皮用組成物
WO2003012050A2 (en) 2001-07-31 2003-02-13 Northeastern University Mitochondrial genome replenishment
US20050153381A1 (en) 2002-02-14 2005-07-14 Marusich Michael F. Immunocapture of mitochondrial protein complexes
AU2004238375A1 (en) 2003-05-13 2004-11-25 The Regents Of The University Of Colorado Diagnostic and therapeutic treatments related to mitochondrial disorders
CA2526493A1 (en) 2003-05-22 2004-12-02 Theraptosis S.A. Means for preventing and treating cellular death and their biological applications
US7407800B1 (en) 2003-09-19 2008-08-05 Pierce Biotechnology, Inc. Method for the isolation of intact mitochondria from cells
EP1709084A4 (en) 2003-12-23 2008-05-28 Nono Inc POLYPEPTIDES FOR MODULATING BINDING OF TRP-CHANNEL PROTEINS AND TRP-ASSOCIATED PROTEINS
US20060024277A1 (en) 2004-07-27 2006-02-02 Sivak Hannah N Method of skin care and/or treatment using extracts enriched in mitochondria
US20100047270A1 (en) 2005-06-10 2010-02-25 Albertsson Per-Aake Use of plant cell membrane for the treatment of obesity
AU2012201710B2 (en) 2006-05-11 2014-01-16 Regenics As Administration of cells and cellular extracts for rejuvenation
AT502353B1 (de) 2006-06-29 2007-07-15 Avl List Gmbh Verfahren und vorrichtung zur konditionierung eines o2-hältigen gases
EP2150117A4 (en) 2007-05-02 2011-10-05 Mclean Hospital Corp METHODS AND COMPOSITIONS FOR MITOCHONDRIA REPLACEMENT THERAPY
WO2008152640A2 (en) 2007-06-13 2008-12-18 Pluristem Ltd. Three dimensional biocompatible scaffolds for ex-vivo expansion and transplantation of stem cells
EP3029061B1 (en) 2008-06-18 2017-09-13 The Texas A&M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
WO2011059547A2 (en) 2009-10-30 2011-05-19 Xenotech, Llc Cryopreservation of cells and subcellular fractions
US8846028B2 (en) 2010-10-28 2014-09-30 The Invention Science Fund I, Llc Mitochondrial enhancement of cells
JP6030067B2 (ja) 2010-12-03 2016-11-24 アラーガン、インコーポレイテッドAllergan,Incorporated 薬学的クリーム組成物および使用法
JP6054301B2 (ja) 2010-12-23 2017-01-11 アマゼンティス エスアーAmazentis Sa ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法
CA2847292A1 (en) 2011-06-29 2013-01-03 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
US20130022666A1 (en) 2011-07-20 2013-01-24 Anna Brzezinska Methods and compositions for transfer of mitochondria into mammalian cells
EP2741757B1 (en) 2011-09-11 2018-05-16 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
US8648034B2 (en) 2011-12-09 2014-02-11 Changhua Christian Hospital Method and applications of peptide-mediated mitochondrial delivery system
WO2013149064A1 (en) 2012-03-30 2013-10-03 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells
US10702556B2 (en) 2012-05-16 2020-07-07 Minovia Therpautices Ltd. Compositions and methods for inducing angiogenesis
EP3459522B1 (en) 2012-12-10 2021-02-17 Regenics AS Use of egg cellular extracts for wound treatment
DE102013225588A1 (de) 2013-12-11 2014-04-17 Henkel Ag & Co. Kgaa Verwendung und Mittel zur Verbesserung der Haarstruktur
JP2017505819A (ja) 2014-02-04 2017-02-23 カイト ファーマ インコーポレイテッドKite Pharma, Inc B細胞悪性腫瘍及び他のがんの治療に有用な自己t細胞を産生する方法、並びにその組成物
EP2918458B1 (en) 2014-03-11 2016-12-07 Autoliv Development AB A vehicle braking arrangement
AU2015289644A1 (en) 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
WO2016008937A1 (en) 2014-07-16 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the intercellular transfer of isolated mitochondria in recipient cells
JP6441472B2 (ja) 2014-09-30 2018-12-19 台灣粒線體應用技術股▲扮▼有限公司Taiwan Mitochondrion Applied Technology Co.,Ltd. 活性成分として外因性ミトコンドリアを含む組成物、ならびにその使用およびそのための細胞修復法
US20170327791A1 (en) * 2014-11-14 2017-11-16 Jcr Pharmaceuticals Co., Ltd Muscular dystrophy therapeutic agent containing pluripotent stem cells derived from dental pulp
GB201500427D0 (en) 2015-01-12 2015-02-25 Isis Innovation Method
EP3244735A4 (en) 2015-01-14 2018-07-04 Calix Ltd Improved pathogen inhibitor
IL299482B2 (en) * 2015-02-26 2025-02-01 Minovia Therapeutics Ltd Mammalian cells are enriched with active mitochondria
US10537594B2 (en) 2015-02-27 2020-01-21 University Of Connecticut Targeted transplantation of mitochondria to hepatocytes
US11903974B2 (en) 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
SI4272834T1 (sl) 2016-01-15 2026-03-31 Beth Israel Deaconess Medical Center, Inc. Terapevtska uporaba mitohondrijev in kombiniranih mitohondrijskih sredstev
MX2019005127A (es) * 2016-11-03 2019-09-26 Exostem Biotec Ltd Poblaciones y productos de células madre mesenquimales y sus usos.
WO2018088874A1 (ko) 2016-11-14 2018-05-17 주식회사 파이안바이오테크놀로지 외래 미토콘드리아를 세포로 전달하는 방법
EP3549589A4 (en) * 2016-11-30 2020-07-15 Paean Biotechnology Inc. PHARMACEUTICAL COMPOSITION CONTAINING MITOCHONDRIA
US20200023005A1 (en) 2017-03-26 2020-01-23 Minovia Therapeutics Ltd. Mitochondrial compositions and methods for treatment of skin and hair
JP7524157B2 (ja) 2018-07-22 2024-07-29 ミノヴィア セラピューティクス リミテッド 脳疾患のミトコンドリア増強療法
JP2021532095A (ja) 2018-07-22 2021-11-25 ミノヴィア セラピューティクス リミテッド 肝臓疾患のミトコンドリア増強療法
JP7458368B2 (ja) 2018-07-22 2024-03-29 ミノヴィア セラピューティクス リミテッド 筋疾患のミトコンドリア増強療法
CN112601532A (zh) 2018-07-22 2021-04-02 米诺维亚疗法有限公司 使用富集有功能性线粒体的干细胞的线粒体增强疗法
US12551504B2 (en) 2018-07-22 2026-02-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of pancreatic diseases
WO2020021536A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
JP2021531288A (ja) 2018-07-22 2021-11-18 ミノヴィア セラピューティクス リミテッド 眼疾患のミトコンドリア増強療法
EP3837359A4 (en) 2018-08-14 2022-05-11 Imel Biotherapeutics, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES OR DISORDERS AND HETEROPLASMIA
WO2020223576A1 (en) 2019-04-30 2020-11-05 Chondrial Therapeutics, Inc. Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy
CA3172402A1 (en) 2020-03-31 2021-10-07 Minovia Therapeutics Ltd. Mitochondria-enriched genetically engineered cells and uses thereof

Similar Documents

Publication Publication Date Title
JP2021532094A5 (https=)
JP2021532091A5 (https=)
Zhidu et al. Translational potential of mesenchymal stem cells in regenerative therapies for human diseases: challenges and opportunities
Kumar et al. The mesenchymal stem cell secretome: A new paradigm towards cell-free therapeutic mode in regenerative medicine
Galderisi et al. Clinical trials based on mesenchymal stromal cells are exponentially increasing: where are we in recent years?
JP2021532095A5 (https=)
JP2021532093A5 (https=)
Shabbir et al. Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen
JP2021531288A5 (https=)
Nair et al. Stem cell therapy in heart failure: Where do we stand today?
Lee et al. Allo-transplantation of mesenchymal stem cells attenuates hepatic injury through IL1Ra dependent macrophage switch in a mouse model of liver disease
Ohnishi et al. Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis
ES2575165T3 (es) Células madre del estroma derivadas de tejido adiposo para su uso en el tratamiento de SRIS
US8354370B2 (en) Administering a biological composition or compositions isolated from self-renewing colony forming somatic cell growth medium to treat diseases and disorders
JP2022519409A5 (https=)
Smolinska et al. Current status of the applications of conditioned media derived from mesenchymal stem cells for regenerative medicine
JP2021531284A5 (https=)
BRPI0708576A2 (pt) composição compreedendo células-tronco embriÈnicas humanas e seus derivados, métodos de uso e métodos de preparação
RU2014108878A (ru) Лечение заболевания периферических сосудов при помощи клеток, полученных из ткани пуповины
CN104955470B (zh) 利用了hmgb1片段的针对脊髄损伤的新型治疗方法
Zhou et al. Therapeutic effects of adipose-derived stem cells-based microtissues on erectile dysfunction in streptozotocin-induced diabetic rats
JP2019513010A (ja) プロスタグランジンe2を用いる、筋再生のための組成物および方法
JPWO2020021539A5 (https=)
JP2021531281A5 (https=)
JPWO2020021540A5 (https=)